ECM
AVBP icon

ExodusPoint Capital Management’s ArriVent BioPharma AVBP Stock Holding History

ExodusPoint Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$439K Sell
19,025
-41,104
-68% -$928K ﹤0.01% 1225
2025
Q4 		$1.21M Buy
60,129
+23,993
+66% +$499K 0.01% 922
2025
Q3 		$667K Sell
36,136
-11,449
-24% -$225K 0.01% 1098
2025
Q2 		$1.04M Buy
47,585
+25,317
+114% +$526K 0.01% 953
2025
Q1 		$412K Buy
+22,268
New +$545K ﹤0.01% 1156

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ExodusPoint Capital Management's AVBP Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its ArriVent BioPharma (AVBP) stake by 68% in Q1 2026, selling an estimated $928K and leaving 19,025 shares worth $439K. The position accounts for ﹤0.01% of the portfolio, ranked #1225.

ExodusPoint Capital Management first reported a position in AVBP in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.21M in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • ExodusPoint Capital Management held 19,025 shares of ArriVent BioPharma worth $439K as of Q1 2026.
  • ExodusPoint Capital Management sold 41,104 ArriVent BioPharma shares in Q1 2026, an estimated $928K.
  • ArriVent BioPharma made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1225 holding.
  • ExodusPoint Capital Management first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 5 quarters since.
  • ExodusPoint Capital Management's ArriVent BioPharma position peaked at $1.21M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.